Sang-ku Yoo
Suwon, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.
Journal: International journal of obesity (2005)
Published: March 13, 2026
Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK/lipophagy activation in adipocytes.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: August 31, 2025
Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects.
Journal: British journal of clinical pharmacology
Published: May 29, 2025
Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease.
Journal: Molecular neurodegeneration
Published: October 20, 2024
Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjects.
Journal: Clinical and translational science
Published: September 09, 2023
Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis.
Journal: British journal of pharmacology
Published: April 06, 2023
Paraoxonase-2 contributes to promoting lipid metabolism and mitochondrial function via autophagy activation.
Journal: Scientific reports
Published: September 08, 2022
Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first-in-class, first-in-human study.
Journal: Clinical and translational science
Published: May 26, 2022
Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity.
Journal: International journal of obesity (2005)
Published: March 11, 2020
Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent.
Journal: Pharmaceutics
Published: November 29, 2019
Inhibitory effects of a β-dunnione compound MB12662 on gastric secretion and ulcers.
Journal: Laboratory animal research
Published: August 06, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026